Lymphoma (includes NHL, HL, CNS Lymphoma)
(AbbVie) Oct 17, 2018 - If granted, IMBRUVICA plus obinutuzumab could become the first chemotherapy-free, anti-CD20 combination approved by the FDA for first-line CLL treatment.
The submission is based on positive results from the Phase 3 iLLUMINATE (PCYC-1130) trial, which showed longer progression-free survival for IMBRUVICA plus...
(Reuters) Oct 10, 2018 - An advisory panel to the U.S. Food and Drug Administration on Wednesday voted unanimously in favor of Celltrion Pharm Inc’s copycat drug of Roche Holding AG’s blood cancer drug Rituxan.
The panel vote comes after the FDA staff reviewers here said Celltrion's biosimilar, CT-P10, is highly similar to...
There are no Lymphoma (includes NHL, HL, CNS Lymphoma) OBR Green articles.